Press "Enter" to skip to content

Moderna’s mRNA coronavirus vaccine caused serious injury in 20% of patients in high dose group, requiring medical intervention

The Moderna vaccine company that’s attempting to use the mRNA technology platform to rapidly create a coronavirus vaccine has been widely accused of a pump-and-dump stock scheme involving the pumping of company stocks with widely-touted press releases that claim positive outcomes for phase 1 vaccine trials.

But buried in Moderna’s own press release is an admission that Moderna’s mRNA-1273 vaccine caused serious injuries in 15% of patients who were injected.

Importantly, the so-called “grade 3 systemic symptoms,” which require medical intervention, appeared after the second round of vaccine injections, underscoring the suspicion that the first vaccine injection sets up the body for an injurious (or even deadly) reaction upon a second exposure to a pathogen.

High-dose subjects suffered “serious adverse events”

The injuries were reported at the 250 ug (microgram) dose levels, and Modern removed those participants from any consideration of antibody reporting, restricting their antibody claims to those who received lower doses.

250 ug is a very tiny dose, just 1/4th of 1/1000th of a gram. Many vaccines inject subjects with similar doses.

“Three of the 15 human guinea pigs in the high dose cohort (250 mcg) suffered a ‘serious adverse event’ within 43 days of receiving Moderna’s jab,” commented Children’s Health Defense:

Moderna did not release its clinical trial study or raw data, but its press release, which was freighted with inconsistencies, acknowledged that three volunteers developed Grade 3 systemic events defined by the FDA as “Preventing daily activity and requiring medical intervention.”

… A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to “every person on earth”.

Moderna skipped animal trials and years of human trials in mad rush to market

Moderna says in its press release that it’s rushing to a phase 3 trial in early July, skipping the normal 1-3 years that it would usually take to determine vaccine safety in phase 1 and phase 2 trials. The fact that the Moderna vaccine caused a 15% rate of serious adverse events during the phase 1 trial hasn’t stopped the vaccine company from exposing others to its risky, experimental vaccine. If anything, the company is doubling down on testing it in more people, albeit at lower doses that it hopes won’t produce the same level of potentially injurious side effects.

CHD further warns:

These outcomes are particularly disappointing because the most hazardous hurdle for the inoculation is still ahead: challenging participants with wild COVID infection. Past attempts at developing COVID vaccines have always faltered at this stage as both humans and animals achieved robust antibody response then sickened and died when exposed to the wild virus.

In other words, even if the mRNA vaccine produces antibodies, that’s nowhere close to achieving a “safe” vaccine. In previous vaccine trials involving animal subjects treated with SARS-CoV-1 pathogens, the animal subjects died when exposed to subsequent infections because the vaccine set up their bodies for a deadly cytokine storm — an “enhanced” immune reaction that leads to systemic inflammation and death.

CHD characterizes the Moderna vaccine trial results as a “catastrophe,” and the CEO of Moderna, Stephane Bancel, previously admitted that mRNA injections into the body actually cause flu-like immune responses that are undesirable:

mRNA creates an immune response. Why? Because a virus is made of mRNA. Like the flu. So if we inject mRNA in a patient, what happens? Your body thinks you just got the flu. And it’s not very good for our drug, because you know all the symptoms of the flu. Not super nice… and the problem of going very high in dose, as you go around your body, you have a ton of side effects.  – Stephane Bancel, CEO of Moderna, TEDxBeaconStreet conference, 2013.

Is it any wonder why Moderna executives are selling their own stock shares like mad, even as they claim to be ramping up a world-changing breakthrough that, if true, would earn stockholders a windfall of profits?

What do Moderna executives know, in other words, that they aren’t telling us?

The most likely answer is that the Moderna vaccine is highly unlikely to ever work without imparting enormous safety risks to patients.

Your use of this website indicates your agreement to these Terms of Service.

All content posted on this site is commentary or opinion and is protected under the 1st Amendment of the United States of America. Hope Holdings and Providence Post are not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. Hope Holdings and Providence Post assume no responsibility for the use or misuse of this material. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners. You must ask permission from them directly to reuse or repost.

This site is a Hope Holdings company website © 2019 All Rights Reserved.